Literature DB >> 31085257

Evaluating the potential of drug eluting contact lenses for treatment of bacterial keratitis using an ex vivo corneal model.

Uloma Ubani-Ukoma1, Daniel Gibson2, Gregory Schultz3, Boladale Olanrewaju Silva4, Anuj Chauhan5.   

Abstract

Corneal infections are treated by multiple instillations of eye drops each day. This study aims to investigate the effectiveness of ofloxacin-loaded contact lenses as prolonged release devices for the treatment of bacterial keratitis. Two silicone hydrogel contact lenses (SHCLs) Senofilcon A (ACUVUE OASYS®) and Narafilcon A (ACUVUE TRUEYE®) were modified by incorporation of ofloxacin alone or with vitamin E (VE). The drug uptake and in vitro release kinetics were investigated and the antibacterial efficacy was assessed against Staphylococcus aureus and Pseudomonas aeruginosa in an ex vivo rabbit corneal model. The in vitro studies showed a higher uptake (p ≤ 0.05) and longer duration of release by Narafilcon A lenses compared to the Senofilcon A lenses. The addition of VE led to a significant increase in duration of release (p < 0.05) for both lenses. The ex vivo studies confirmed the effectiveness of the ofloxacin-loaded lenses in the reduction of bacterial load to clinically insignificant levels and ofloxacin-vitamin E-loaded Narafilcon A lenses in the reduction of bacteria on the corneas to undetectable levels. Antibiotic-loaded lenses are effective in the treatment of ocular infections. Incorporation of vitamin E will sustain this effect and eliminate the need for multiple instillations of eye drops.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bacterial keratitis; Ex vivo corneal model; Ofloxacin; Prolonged release; Silicone hydrogel contact lens; Vitamin E

Mesh:

Substances:

Year:  2019        PMID: 31085257     DOI: 10.1016/j.ijpharm.2019.05.031

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  7 in total

Review 1.  Nanoparticles for the treatment of glaucoma-associated neuroinflammation.

Authors:  Lidawani Lambuk; Nurfatihah Azlyna Ahmad Suhaimi; Muhammad Zulfiqah Sadikan; Azliana Jusnida Ahmad Jafri; Suhana Ahmad; Nurul Alimah Abdul Nasir; Vuk Uskoković; Ramlah Kadir; Rohimah Mohamud
Journal:  Eye Vis (Lond)       Date:  2022-07-02

2.  Development and Characterization of PLGA Nanoparticle-Laden Hydrogels for Sustained Ocular Delivery of Norfloxacin in the Treatment of Pseudomonas Keratitis: An Experimental Study.

Authors:  Rana M Gebreel; Noha A Edris; Hala M Elmofty; Mina I Tadros; Mohamed A El-Nabarawi; Doaa H Hassan
Journal:  Drug Des Devel Ther       Date:  2021-02-05       Impact factor: 4.162

3.  An ex vivo cornea infection model.

Authors:  Uloma Ubani-Ukoma; Anuj Chauhan; Gregory Schultz; Daniel J Gibson
Journal:  MethodsX       Date:  2020-04-07

Review 4.  Corneal Infection Models: Tools to Investigate the Role of Biofilms in Bacterial Keratitis.

Authors:  Lucy Urwin; Katarzyna Okurowska; Grace Crowther; Sanhita Roy; Prashant Garg; Esther Karunakaran; Sheila MacNeil; Lynda J Partridge; Luke R Green; Peter N Monk
Journal:  Cells       Date:  2020-11-10       Impact factor: 6.600

5.  Key Role of Staphylococcal Fibronectin-Binding Proteins During the Initial Stage of Staphylococcus aureus Keratitis in Humans.

Authors:  Corantin Maurin; Emilie Courrier; Zhiguo He; Josselin Rigaill; Jérôme Josse; Frédéric Laurent; Philippe Gain; Gilles Thuret; Paul O Verhoeven
Journal:  Front Cell Infect Microbiol       Date:  2021-11-09       Impact factor: 5.293

Review 6.  Considerations for Polymers Used in Ocular Drug Delivery.

Authors:  Megan M Allyn; Richard H Luo; Elle B Hellwarth; Katelyn E Swindle-Reilly
Journal:  Front Med (Lausanne)       Date:  2022-01-28

7.  "Kill-release" antibacterial polysaccharides multilayer coating based therapeutic contact lens for effective bacterial keratitis treatment.

Authors:  Rui Wang; Duoduo Lu; Hui Wang; Haoyu Zou; Ting Bai; Chulei Feng; Quankui Lin
Journal:  RSC Adv       Date:  2021-07-30       Impact factor: 3.361

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.